Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.

Gabler L, Lötsch D, Kirchhofer D, van Schoonhoven S, Schmidt HM, Mayr L, Pirker C, Neumayer K, Dinhof C, Kastler L, Azizi AA, Dorfer C, Czech T, Haberler C, Peyrl A, Kumar R, Slavc I, Spiegl-Kreinecker S, Gojo J, Berger W.

Acta Neuropathol Commun. 2019 Aug 7;7(1):128. doi: 10.1186/s40478-019-0775-6.

2.

Epigenomics and Single-cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis.

Halbritter F, Farlik M, Schwentner R, Jug G, Fortelny N, Schnoller T, Pisa H, Schuster LC, Reinprecht A, Czech T, Gojo J, Holter W, Minkov M, Bauer WM, Simonitsch-Klupp I, Bock C, Hutter C.

Cancer Discov. 2019 Jul 25. pii: CD-19-0138. doi: 10.1158/2159-8290.CD-19-0138. [Epub ahead of print]

PMID:
31345789
3.

Resolving medulloblastoma cellular architecture by single-cell genomics.

Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, DeWitt JC, Groves A, Mayr L, Weisman HR, Richman AR, Shore ME, Goumnerova L, Rosencrance C, Carter RA, Phoenix TN, Hadley JL, Tong Y, Houston J, Ashmun RA, DeCuypere M, Sharma T, Flasch D, Silkov A, Ligon KL, Pomeroy SL, Rivera MN, Rozenblatt-Rosen O, Rusert JM, Wechsler-Reya RJ, Li XN, Peyrl A, Gojo J, Kirchhofer D, Lötsch D, Czech T, Dorfer C, Haberler C, Geyeregger R, Halfmann A, Gawad C, Easton J, Pfister SM, Regev A, Gajjar A, Orr BA, Slavc I, Robinson GW, Bernstein BE, Suvà ML, Northcott PA.

Nature. 2019 Aug;572(7767):74-79. doi: 10.1038/s41586-019-1434-6. Epub 2019 Jul 24.

PMID:
31341285
4.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML.

Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.

PMID:
31327527
5.

Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage.

Reisinger D, Gojo J, Kasprian G, Haberler C, Peyrl A, Azizi AA, Mayr L, Chocholous M, Kool M, Czech T, Slavc I.

Neurosurgery. 2019 May 7. pii: nyz148. doi: 10.1093/neuros/nyz148. [Epub ahead of print]

PMID:
31065705
6.

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.

Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, Pichler J, Weis S, Kumar R, Webersinke G, Gruber A, Berger W.

Neuro Oncol. 2018 Nov 12;20(12):1584-1593. doi: 10.1093/neuonc/noy104.

PMID:
30010853
7.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

8.

From Symptom to Diagnosis-The Prediagnostic Symptomatic Interval of Pediatric Central Nervous System Tumors in Austria.

Azizi AA, Heßler K, Leiss U, Grylli C, Chocholous M, Peyrl A, Gojo J, Slavc I.

Pediatr Neurol. 2017 Nov;76:27-36. doi: 10.1016/j.pediatrneurol.2017.08.006. Epub 2017 Aug 18.

PMID:
28935367
9.

Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies.

Gojo J, Sauermann R, Knaack U, Slavc I, Peyrl A.

Drugs R D. 2017 Sep;17(3):469-474. doi: 10.1007/s40268-017-0190-z.

10.

Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.

Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, Araki A, Brandstetter A, Mohr T, Hovestadt V, Chavez L, Kirchhofer D, Ricken G, Stefanits H, Korshunov A, Pfister SM, Dieckmann K, Azizi AA, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C.

Neuro Oncol. 2017 Sep 1;19(9):1183-1194. doi: 10.1093/neuonc/nox027.

11.

Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.

Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, Dieckmann K, Ambros IM, Ambros PF, Slavc I, Haberler C.

Acta Neuropathol Commun. 2016 Aug 22;4(1):88. doi: 10.1186/s40478-016-0349-9.

12.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M.

Cell. 2016 Feb 25;164(5):1060-1072. doi: 10.1016/j.cell.2016.01.015.

13.

Calpain-mediated integrin deregulation as a novel mode of action for the anticancer gallium compound KP46.

Jungwirth U, Gojo J, Tuder T, Walko G, Holcmann M, Schöfl T, Nowikovsky K, Wilfinger N, Schoonhoven S, Kowol CR, Lemmens-Gruber R, Heffeter P, Keppler BK, Berger W.

Mol Cancer Ther. 2014 Oct;13(10):2436-49. doi: 10.1158/1535-7163.MCT-14-0087. Epub 2014 Jul 31.

14.

Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients.

Peyrl A, Chocholous M, Azizi AA, Czech T, Dorfer C, Mitteregger D, Gojo J, Minichmayr E, Slavc I.

J Neurooncol. 2014 Oct;120(1):139-45. doi: 10.1007/s11060-014-1531-1. Epub 2014 Jul 14.

PMID:
25017328
15.

Anticancer activity of methyl-substituted oxaliplatin analogs.

Jungwirth U, Xanthos DN, Gojo J, Bytzek AK, Körner W, Heffeter P, Abramkin SA, Jakupec MA, Hartinger CG, Windberger U, Galanski M, Keppler BK, Berger W.

Mol Pharmacol. 2012 May;81(5):719-28. doi: 10.1124/mol.111.077321. Epub 2012 Feb 13.

Supplemental Content

Support Center